Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12

 Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12

Pfizer and BioNTech Initiate COVID-19 Vaccine Trial in Children Under 12

Shots:

  • The companies have started testing BNT162b2 in children aged 6-11yrs. with initial results anticipated in H2’21. The companies are planning to expand the vaccination to that age range by early 2022
  • The companies plan to initiate the safety of BNT162b2 (10/20/30µg) vs PBO in P-I/II trial in 144-participant
  • Pfizer and BioNTech later plan to expand the trial to 4,500-participant to evaluate the safety, tolerability and immune response of the vaccine in kids. Meanwhile, Pfizer has been testing the vaccine in children from aged 12-15yrs. and anticipating results in coming weeks

Click here ­to­ read full press release/ article | Ref: Reuters | Image: WebMD

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post